R. Scott McKenzie

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma.

Patrick J. Stiff, R. Scott McKenzie, David S. Alberts et al. · Journal of Clinical Oncology · 1994 · 51 citations

Pharmacy, Oncology, Pharmacokinetics +17

Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer

Marie‐Hélène Lafeuille, Amanda Melina Grittner, Patrick Lefèbvre et al. · Journal of Managed Care Pharmacy · 2014 · 34 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

Frank J. Papatheofanis, R. Scott McKenzie, Samir H. Mody et al. · Current Medical Research and Opinion · 2006 · 30 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15

Association of anemia with worsened activities of daily living and health-related quality of life scores derived from the Minimum Data Set in long-term care residents

Robert A. Bailey, Gregory Reardon, Michael Wasserman et al. · Health and Quality of Life Outcomes · 2012 · 29 citations · Full text

Medicine, Geriatric Medicine, Hematology +17

Impact of limiting erythropoiesis‐stimulating agent use for chemotherapy‐induced anemia on the United States blood supply margin

Francis Vekeman, Brahim Bookhart, Joshua White et al. · Transfusion · 2009 · 28 citations

Medicine, Health Services Administration, Hematology +12